PHPBiotech.wikiThe PHP Biotech Reference

Patents and publications

From PHPBiotech.wiki, a sourced reference on PHP Biotech, a preclinical oncology company

By the PHP Biotech Wiki editorial team · Published · Last updated

Short answer: PHP Biotech has two published U.S. patent applications, US 2023/0364204 A1 (anti-tumor peptides) and US 2026/0041783 A1 (the nanobody platform), both listed as pending, and one peer-reviewed paper, a 2024 Molecules study of the 3-NAntC peptide.[1][2][3] The company says it holds four U.S. patent applications in total.[4][5]

Disclosure: PHPBiotech.wiki is a reference compiled from public sources. It is not the official website of PHP Biotech International Inc.; it is produced by a marketing agency that works for PHP Biotech. It is not written or reviewed by the U.S. Food and Drug Administration or any other regulator, by the journal that published the company’s research, or by any patent office. Nothing on this site is medical advice. PHP53-nb is an investigational, preclinical product: it is not approved for any use and is not available to patients. Facts are cited to public registries, PubMed, patent records, archived web pages, press releases and the company’s own website. See the editorial policy.

Which patent applications have been published?

Published U.S. patent applications assigned to PHP Biotech International Inc.
NumberTitleFiledPublishedStatus (Google Patents, 4 Oct 2026)
US 2023/0364204 A1
(appl. 18/313,141)		Bioactive Peptides, Compositions, Production Process, and Use of Bioactive Peptides as Anti-Tumoral Agents5 May 202316 Nov 2023Pending[1]
US 2026/0041783 A1
(appl. 19/223,678)		Nanobody platform, Peptide-modified Nanobody, Production Process, and Use30 May 202512 Feb 2026Pending[2]

Both applications name Moacyr Ramos Bighetti and Patricia Heloise Alves Bezerra as inventors and PHP Biotech International Inc. as the assignee.[1][2] The first covers peptides derived from the C-terminal region of crotoxin B for use against tumors; the second covers a nanobody with peptides placed in its CDR1 and CDR3 regions.[1][2]

How many patent applications does the company say it has?

The company’s blog posts say it has four U.S. patent applications, covering the platform, the recombinant production technology, the therapeutic peptide library and PHP53-nb.[4] A September 2026 press release refers to “three therapeutic assets and four U.S. patent applications”.[5] This wiki found two published applications; unpublished applications are not public, so the other two could not be checked.[1][2]

Has any patent been granted?

No granted U.S. patent assigned to PHP Biotech was found as of 4 October 2026; both published applications are listed as pending.[1][2] The company’s website uses the word “patented” for PHP53-nb and its platform; see Company claims in context.[6][7]

What peer-reviewed research has been published?

Bezerra P, Motti EF. “3-NAntC: A Potent Crotoxin B-Derived Peptide against the Triple-Negative MDA-MB-231 Breast Cancer Cell Line.” Molecules, volume 29, issue 7, article 1646, published 6 April 2024.[3] The study tested the 3-NAntC peptide on its own, not PHP53-nb, in breast cancer cell lines and in zebrafish.[3] The authors’ affiliation is PHP Biotech International Inc., Keller, Texas, and the paper states that the company fully funded the research and employed the authors.[3]

Are there other publications?

This wiki found no other peer-reviewed paper on 3-NAntC or PHP53-nb in PubMed as of 4 October 2026.[3] The company has described further results on its website and in press releases, including the September 2026 uPAR announcement.[8][9] Those are listed as company statements.

Frequently asked questions

Does PHP Biotech have patents?

It has two published U.S. patent applications, both pending as of 4 October 2026, and says it has four applications in total. No granted patent was found.

Who are the inventors?

Moacyr Ramos Bighetti and Patricia Heloise Alves Bezerra are named on both published applications.

Has PHP53-nb been described in a journal?

Not that this wiki found. The 2024 Molecules paper covers the 3-NAntC peptide alone.

See also

References

  1. ^ a b c d e f US 2023/0364204 A1, “Bioactive Peptides, Compositions, Production Process, and Use of Bioactive Peptides as Anti-Tumoral Agents” (application 18/313,141). Google Patents (U.S. Patent and Trademark Office data). Retrieved 4 October 2026.
  2. ^ a b c d e f US 2026/0041783 A1, “Nanobody platform, Peptide-modified Nanobody, Production Process, and Use” (application 19/223,678). Google Patents (U.S. Patent and Trademark Office data). Retrieved 4 October 2026.
  3. ^ a b c d e Bezerra P, Motti EF. “3-NAntC: A Potent Crotoxin B-Derived Peptide against the Triple-Negative MDA-MB-231 Breast Cancer Cell Line.” Molecules 2024;29(7):1646. doi:10.3390/molecules29071646. PMID 38611925. PubMed, U.S. National Library of Medicine. Retrieved 4 October 2026.
  4. ^ a b “What Is a Nanobody?” (blog post, 17 August 2026). PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  5. ^ a b “PHP Biotech to Present Nanobody Panel and Sponsor 3rd Annual Oncology Venture, Innovation & Partnering Summit” (25 September 2026). PressAdvantage newsroom (company press release). Retrieved 4 October 2026.
  6. ^ Home page. PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  7. ^ “Platform”. PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  8. ^ “Our Science” (including the science FAQ). PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  9. ^ “PHP Biotech Identifies uPAR as the Cellular Entry Receptor for Its PHP53-nb Anti-Tumor Nanobody” (Southlake, Texas, 18 September 2026). PressAdvantage newsroom (company press release). Retrieved 4 October 2026.